Evidence map›Paper›PMID 40120139›Full record

ArticleCancer communications (London, England)2025

Immunosuppressive JAG2

Chenyang Wang, Moran Yang, Yujing Zhong, Kankan Cao, Xueling Wang, Chen Zhang, Yiying Wang, Mengdi He, Jiaqi Lu, Guodong Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. A prognostic model based on ScissorTranslational cancer research · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Organoids glimpse: the nexus for diverse tumor heterogeneity.Frontiers in cell and developmental biology · 2026
    Review
  12. Review
  13. Immunosuppressive JAG2Cancer communications (London, England) · 2025
    Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chenyang WangShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.ORCID 0009-0007-6895-4897
Moran YangShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.
Yujing ZhongShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.
Kankan CaoShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.
Xueling WangShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.
Chen ZhangShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.
Yiying WangShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.
Mengdi HeShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.
Jiaqi LuShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.
Guodong ZhangDepartment of Gynecologic Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.
Yan HuangDepartment of Gynecologic Oncology, Shanghai Cancer Center, Fudan University, Shanghai, P. R. China.
Haiou LiuShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.ORCID 0000-0003-0200-8981

Funding

National Natural Science Foundation of China 82072881National Natural Science Foundation of China 82203665National Natural Science Foundation of China 82273205National Natural Science Foundation of China 82473274Natural Science Foundation of Shanghai 23ZR1408300Shanghai Clinical Research Center for Gynecological Diseases 22MC1940200Shanghai Science and Technology Innovation Action Plan 23Y11901800Shanghai Science and Technology Innovation Action Plan 23Y11909500
6 · The paper itself

Abstract

backgroundTumor-associated neutrophils (TANs) play a critical role in modulating immune responses and exhibit significant heterogeneity. Our previous study demonstrated that jagged canonical Notch ligand 2 (JAG2)

methodsHGSOC samples were collected, with 274 samples constituting two independent cohorts (training and validation cohorts) and an additional 30 samples utilized to establish patient-derived tumor organoids (PDTOs). We characterized the number and phenotype of JAG2

resultsJAG2

conclusionsThe emergence of JAG2

Indexed as

Immune Checkpoint InhibitorsJagged-2 ProteinNeutrophilsOvarian NeoplasmsProgrammed Cell Death 1 ReceptorT-Lymphocytes, RegulatoryAnimalsCell DifferentiationCell Line, TumorFemaleHumansMiceTumor MicroenvironmentImmune Checkpoint InhibitorsJAG2 protein, humanJagged-2 ProteinPDCD1 protein, humanProgrammed Cell Death 1 Receptoreffector regulatory T cellshigh‐grade serous ovarian cancerJagged2programmed cell death 1Tumor‐associated neutrophils

Identifiers

PMID40120139
PMCPMC12328091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.